FrancophonIA/ELRC3.0 huggingface dataset:
English: Tritazide can also be available in the EU and the EEA under other trade names: Tritace Plus, Triatec Plus, Triatec Comp, Tritace Comp, Tritace Comb, Triatec Composto, Triatec Composto Forte, Cardace Comp, Cardace Plus, Cotriatec, Delix Plus, Ramilich Comp, Tritace HCT, Triatec HCT, Ramipril e Idrocloritiazide, Ramicor D, and Triatec Comp Mite,Hypren Plus, Hypren Plus Forte, Vesdil Plus, Ramipril HCT Zentiva, Unipril Diur, Idroquark..
Slovenian: Zdravilo Tritazide je lahko v EU in EGP na voljo tudi pod naslednjimi imeni: Tritace Plus, Triatec Plus, Triatec Comp, Tritace Comp, Tritace Comb, Triatec Composto, Triatec Composto Forte, Cardace Comp, Cardace Plus, Cotriatec, Delix Plus, Ramilich Comp, Tritace HCT, Triatec HCT, Ramipril e Idrocloritiazide, Ramicor D, and Triatec Comp Mite,Hypren Plus, Hypren Plus Forte, Vesdil Plus, Ramipril HCT Zentiva, Unipril Diur in Idroquark.
English: Tritazide is authorised in the European Union (EU) via national procedures.
Slovenian: Zdravilo Tritazide je v Evropski uniji (EU) odobreno z nacionalnimi postopki.
English: Ref. EMEA/CHMP/204584/2009
Slovenian: EMEA/203002/2009
English: Why was Tritazide reviewed?
Slovenian: Zakaj je bilo zdravilo Tritazide pregledano?
English: In most cases the initial recommended dose was the same, but there were differences with respect to subsequent titration (both in terms of frequency of increase and maximum daily dose).
Slovenian: V večini primerov je bil začetni priporočeni odmerek enak, vendar so obstajale razlike glede nadaljnje titracije (glede pogostnosti povečanja in največjega dnevnega odmerka).
English: Tritazide and associated names should be started at the lowest available dosage.
Slovenian: Zdravilo Tritazide in z njim povezana imena je treba začeti jemati pri najnižjem odmerku, ki je na voljo.
English: The European Medicines Agency (EMEA) has completed a review of Tritazide.
Slovenian: Evropska agencija za zdravila (EMEA) je zaključila pregled zdravila Tritazide.
English: The dose should be individualised according to the patient profile (see section 4.4) and blood pressure control.
Slovenian: Odmerek je treba prilagoditi posamezniku skladno z njegovim profilom (glejte poglavje 4.4) in nadzorom krvnega tlaka.
English: • Treatment of hypertension
Slovenian: • zdravljenje hipertenzije,
English: The CHMP included also new warnings for: pregnancy, surgery, electrolyte disturbances, and cough.
Slovenian: CHMP je poleg tega vključil tudi nova opozorila za: nosečnost, kirurške posege, elektrolitske motnje in kašelj.
English: The company that markets Tritazide is Sanofi-aventis.
Slovenian: Družba, ki trži zdravilo Tritazide, je Sanofi-aventis.
English: • Clinically relevant electrolyte disturbances which may worsen following treatment with
Slovenian: • Klinično pomembne motnje elektrolitov, ki lahko poslabšajo zdravljenje z zdravilom
English: The CHMP adopted the following harmonised wording:
Slovenian: CHMP je sprejel naslednje usklajeno besedilo:
English: The CHMP discussed the areas where there was a divergence identified in the dose recommendations.
Slovenian: CHMP je razpravljal o področjih, na katerih je prišlo do razhajanj pri priporočilih glede odmerka.
English: 4.5 Interactions
Slovenian: 4.5 Medsebojno delovanje
English: It works by increasing urine output, reducing the amount of fluid in the blood and lowering the blood pressure.
Slovenian: Deluje tako, da poveča tvorjenje urina in pri tem zmanjša količino tekočine v krvi, s tem pa tudi zniža krvni tlak.
English: This is in line with the recommendation of the CHMP's Pharmacovigilance Working Party on use of ACE inhibitors in pregnancy.
Slovenian: To je skladno s priporočilom delovne skupine za farmakovigilanco odbora CHMP v povezavi z uporabo zaviralcev angiotenzinske konvertaze med nosečnostjo.
English: • Severe impairment of liver function, hepatic encephalopathy
Slovenian: • Močno poslabšana jetrna funkcija, hepatična encefalopatija.
English: • Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see section 4.5)
Slovenian: • Zunajtelesna zdravljenja, pri katerih pride do stika krvi z negativno naelektrenimi površinami (glejte poglavje 4.5).
English: This has led to divergences across member states on the way the medicine can be used, as seen in the differences observed in the Summaries of Product Characteristics (SPCs), labelling and package leaflets in the countries where the product is marketed.
Slovenian: To je v državah članicah privedlo do razhajanj glede uporabe zdravila, kot je razvidno iz razlik v povzetkih glavnih značilnosti zdravila, označevanja in navodila za uporabo v državah, v katerih je zdravilo na trgu.
English: The combination ramipril 2.5 mg/ HCTZ 12.5 mg led to greater reduction in blood pressure than the treatment with individual components and the combination of 5 mg/25 mg produced a better therapeutic effect than doubling the ramipril dose to 10 mg.
Slovenian: Kombinacija ramiprila 2,5 mg/hidroklorotiazid 12,5 mg je povzročila večji padec krvnega tlaka kot zdravljenje s posamezno zdravilo učinkovino, kombinacija 5 mg/25 mg pa je imela za posledico boljše zdravilne učinke kot podvojitev odmerka ramiprila na 10 mg.
English: • 2nd and 3rd trimester of pregnancy (see section 4.4 and 4.6)
Slovenian: • 2. in 3. tromesečje nosečnosti (glejte poglavji 4.4 in 4.6).
English: The CHMP endorsed the current list of products which interact or may interact with Tritazide, including additional text reinforcing lithium toxicity.
Slovenian: CHMP je podprl trenutno veljaven seznam zdravil, ki medsebojno delujejo z zdravilom Tritazide, ali bi do tega utegnilo priti, vključno z dodatnim besedilom, ki je poudaril toksičnost litija.
English: • Severe impairment of renal function with a creatinine clearance below 30 ml/min in undialysed patients
Slovenian: • Močno poslabšana ledvična funkcija, kjer je očistek kreatinina pri nedializiranih bolnikih manjši od 30 ml/min.
English: The majority of the contraindications are related to use of ramipril as a component of Tritazide.
Slovenian: Večina kontraindikacij je povezanih z uporabo ramiprila kot sestavine zdravila Tritazide.
English: The CHMP included under this session the warning about primary hyperaldosteronism, therefore adopted the following harmonised wording: The combination ramipril + hydrochlorothiazide does not represent a treatment of choice for primary hyperaldosteronism.
Slovenian: CHMP je v ta odstavek vključil opozorilo o primarnem hiperaldosterizmu, zato je sprejel naslednje usklajeno besedilo: Kombinacija ramiprila in hidroklorotiazida ne predstavlja zdravljenja prve izbire za primarni hiperaldosteronizem.
English: If ramipril + hydrochlorothiazide is used in a patient with primary hyperaldosteronism, then careful monitoring of plasma potassium level is required.
Slovenian: Če se ramipril in hidroklorotiazid uporabi pri bolniku s primarnim hiperaldosteronizmom, potem je potrebno pozorno spremljanje ravni kalija v plazmi.
English: Hydrochlorothiazide (HCTZ) is a diuretic.
Slovenian: Hidroklorotiazid (HCTZ) je diuretik.
English: The CHMP noted that some of the contraindications in local SPCs (such as acute hypertension or primary aldosteronism) were in fact non-indications.
Slovenian: CHMP je ugotovil, da so bile nekatere kontraindikacije v lokalnih povzetkih glavnih značilnosti zdravila (kot so akutna hipertenzija ali primarni aldosteronizem) dejansko neindikacije.
English: Considering that no major concern can be established concerning the safety, efficacy and clinical adverse event of the ramipril/HCTZ combination in non responders to HCTZ and ramipril alone, the CHMP adopted the following two harmonised wordings for indications:
Slovenian: Če upoštevamo, da glede varnosti, učinkovitosti in kliničnih neželenih učinkov ni bilo ugotovljenih večjih zadržkov za kombinacijo ramipril/hidroklorotiazid pri bolnikih, ki se niso odzivali samo na hidroklorotiazid ali samo na ramipril, je CHMP za indikacije sprejel naslednji dve usklajeni besedili:
English: • Significant bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney
Slovenian: • Znatna obojestranska stenoza renalne arterije ali stenoza renalne arterije pri eni sami delujoči ledvici.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Tritazide in the European Union and the European Economic Area (EEA).
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri tej agenciji je zaključil, da je treba v Evropski uniji in Evropskem gospodarskem prostoru (EGP) uskladiti podatke o predpisovanju zdravila Tritazide.
English: TRITAZIDE (see section 4.4)
Slovenian: TRITAZIDE (glejte poglavje 4.4).
English: The CHMP adopted the harmonised wording:
Slovenian: Odbor CHMP je sprejel usklajeno besedilo:
English: The CHMP noted inconsistencies in the wording of the indication across countries, with terms including ‘essential hypertension', ‘arterial hypertension' and ‘arterial essential hypertension' being used.
Slovenian: CHMP je opazil neskladnosti v besedilih za indikacije med državami, kjer so uporabljali izraze „esencialna hipertenzija“, „arterijska hipertenzija“ in „arterijska esencialna hipertenzija“.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SPCs, labelling and package leaflets should be harmonised across the EU.
Slovenian: CHMP je ob upoštevanju predloženih podatkov in znanstvene razprave v okviru Odbora menil, da je treba povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo uskladiti v vsej EU.
English: What is Tritazide?
Slovenian: Kaj je zdravilo Tritazide?
English: The administration of the fixed combination of ramipril and hydrochlorothiazide is usually recommended after dosage titration with one of the individual components.
Slovenian: Dajanje fiksne kombinacije ramiprila in hidroklorotiazida se navadno priporoča po titraciji odmerka z eno od posameznih zdravilnih učinkovin.
English: The CHMP also noted that there were limited trial data regarding titration steps with the combination.
Slovenian: CHMP je poleg tega ugotovil tudi, da za korake titracije kombiniranega zdravila obstajajo omejeni podatki o preskušanju.
English: • This fixed dose combination is indicated in patients whose blood pressure is not adequately controlled with ramipril alone or hydrochlorothiazide alone.
Slovenian: • ta kombinacija fiksnih odmerkov je indicirana za bolnike, pri katerih krvnega tlaka ni mogoče primerno nadzorovati samo z ramiprilom ali samo s hidroklorotiazidom.
English: The CHMP highlighted that fact that the indication should be hypertension, and as add-on therapy when each monotherapy has failed.
Slovenian: CHMP je poudaril dejstvo, da bi indikacija morala biti hipertenzija ter uporaba zdravila kot dodatnega zdravljenja, kadar odpovesta obe monoterapiji.
English: 2.5/12.5 mg, 5/12.5 mg, 5/25 mg
Slovenian: Vprašanja in odgovori v zvezi z napotitvijo za zdravilo Tritazide tablete, ki vsebujejo 2,5/12,5 mg, 5/12,5 mg, 5/25 mg ramiprila in hidroklorotiazida
English: Tritazide contains two active substances, ramipril and hydrochlorothiazide.
Slovenian: Zdravilo Tritazide vsebuje dve zdravilni učinkovini: ramipril in hidroklorotiazid.
English: Tritazide is used in the treatment of hypertension and it is indicated in patients whose blood pressure is not adequately controlled with ramipril alone or hydrochlorothiazide alone.
Slovenian: Zdravilo Tritazide se uporablja za zdravljenje hipertenzije in je indicirano za uporabo pri bolnikih, pri katerih krvnega tlaka ni mogoče primerno nadzorovati samo z ramiprilom ali hidroklorotiazidom.
English: They are extended with the contraindications of HCTZ.
Slovenian: Te kontraindikacije so razširjene s kontraindikacijami za hidroklorotiazid.
English: • History of angioedema (hereditary, idiopathic or due to previous angioedema wit ACE
Slovenian: • Anamneza angioedema (dednega, idiopatičnega ali zaradi predhodnega angioedema z zaviralci angiotenzinske konvertaze ali antagonisti receptorjev angiotenzina II).
English: Ramipril is an angiotensin converting enzyme (ACE) inhibitor.
Slovenian: Ramipril je zaviralec angiotenzinske konvertaze.
English: • Lactation (see section 4.6)
Slovenian: • Dojenje (glejte poglavje 4.6).
English: On 18 January 2008, the European Commission referred the matter to the Committee for Medicinal Products for Human Use (CHMP) in order to harmonise the marketing authorisations for Tritazide in the EU and the EEA.
Slovenian: Da bi Evropska komisija uskladila dovoljenja za promet z zdravilom Tritazide v EU in EGP, je dne 18. januarja 2008 zadevo napotila na Odbor za zdravila za uporabo v humani medicini (CHMP).
English: Tritazide has been identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Slovenian: Koordinacijska skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila v humani medicini (CMD(h)) je ugotovila, da je za zdravilo Tritazide potrebno usklajevanje.
English: If necessary, the dose can be progressively increased to achieve target blood pressure; the maximum permitted doses are 10 mg of ramipril and 25 mg of hydrochlorothiazide daily.
Slovenian: Največja dovoljena odmerka sta 10 mg ramiprila in 25 mg hidroklorotiazida dnevno.
English: • Hypersensitivity to the active substance, to any of the excipients or any other ACE (Angiotensin
Slovenian: • Preobčutljivost na zdravilno učinkovino na katerobkoli od pomožnih snovi ali druge zaviralce angiotenzinske konvertaze) (glejte poglavje 6.1).
English: Applicant company name, address
Slovenian: Predlagatelj ime podjetja, naslov
English: Annex I List of medicinal products and presentations
Slovenian: Seznam zdravil in oblik
English: Spain
Slovenian: Velika Britanija
English: End of December 2018
Slovenian: konca decembra 2018
English: The final study report should be submitted by:
Slovenian: Končno poročilo o študiji je treba predložiti do:
English: The protocol of this study should be submitted to the PRAC within 6 months after notification of the EC Decision.
Slovenian: Protokol študije je treba odboru PRAC predložiti v roku 6 mesecev od izdaje obvestila o odločbi ES.
English: National Competent Authorities of Member States or Reference Member States, if applicable, shall ensure that the following conditions are fulfilled by the MAHs:
Slovenian: Pristojni nacionalni organi držav članic ali referenčnih držav članic bodo zagotovili, kadar je to primerno, da imetniki dovoljenj za promet z zdravilom izpolnjujejo naslednje pogoje:
English: For chlormadinone-containing combined hormonal contraceptives The MAHs for chlormadinone containing CHCs should carry out a post-authorisation safety study to compare the risk of VTE with chlormadinone/ethinyestradiol versus levonorgestrel/ethinyestradiol.
Slovenian: Imetniki dovoljenj za promet s kombiniranimi hormonskimi kontraceptivi, ki vsebujejo klormadinon, morajo opraviti študijo varnosti zdravila v obdobju trženja za proučitev tveganja za VTE pri uporabi klormadinona/etinilestradiola v primerjavi z levonorgestrelom/etinilestradiolom.
English: Memantine Mylan should be given once a day at the same time every day.
Slovenian: Zdravilo Memantine Mylan se daje enkrat dnevno, vsak dan ob istem času.
English: Memantine Mylan is a medicine used to treat patients with moderate to severe Alzheimer's disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Slovenian: Memantine Mylan je zdravilo, ki se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo, vrsto demence (možganske bolezni), ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
English: To prevent side effects, the dose of Memantine Mylan is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Slovenian: Da se preprečijo neželeni učinki, se odmerek zdravila Memantine Mylan v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg, drugi teden 10 mg, tretji teden pa 15 mg. Od četrtega tedna naprej je priporočeni vzdrževalni odmerek 20 mg enkrat dnevno.
English: What measures are being taken to ensure the safe and effective use of Memantine Mylan?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Memantine Mylan?
English: This is a summary of the European public assessment report (EPAR) for Memantine Mylan.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Memantine Mylan.
English: The Committee recommended that Memantine Mylan be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Memantine Mylan odobri za uporabo v EU.
English: The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Memantine Mylan should be reassessed on a regular basis.
Slovenian: Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom Memantine Mylan ponovno ocenjevati v rednih intervalih.
English: This means that Memantine Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Ebixa.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Ebixa.
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Mylan by the patient.
Slovenian: Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo jemanje zdravila Memantine Mylan.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Memantine Mylan on 22 April 2013.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Memantine Mylan, veljavno po vsej Evropski uniji, odobrila dne 22. aprila 2013.
English: Memantine Mylan is available as 10 mg and 20 mg tablets and can only be obtained with a prescription.
Slovenian: Zdravilo Memantine Mylan je na voljo v obliki 10- in 20-miligramskih tablet in se izdaja le na recept.
English: Because Memantine Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Memantine Mylan generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: What are the benefits and risks of Memantine Mylan?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Memantine Mylan?
English: The full EPAR for Memantine Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: For more information about treatment with Memantine Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Memantine Mylan preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease.
Slovenian: kako glutamat prenaša signale v možganih, se povezujejo z izgubo spomina, kakršno je opaziti pri Alzheimerjevi bolezni.
English: Memantine Mylan memantine
Slovenian: Memantine Mylan memantin
English: In addition, overstimulation of the NMDA receptors may result in cell damage or death.
Slovenian: Poleg tega lahko prekomerna stimulacija receptorjev NMDA
English: Safety information has been included in the summary of product characteristics and the package leaflet for Memantine Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Memantine Mylan so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: Because Memantine Mylan is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Ebixa.
Slovenian: Ker je zdravilo Memantine Mylan generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Ebixa.
English: What is Memantine Mylan and what is it used for?
Slovenian: Kaj je zdravilo Memantine Mylan in za kaj se uporablja?
English: For practical information about using Memantine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Memantine Mylan naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Other information about Memantine Mylan
Slovenian: Druge informacije o zdravilu Memantine Mylan
English: Memantine Mylan is a ‘generic medicine'.
Slovenian: Zdravilo Memantine Mylan je „generično“ zdravilo.
English: The active substance in Memantine Mylan, memantine, is an antidementia medicine.
Slovenian: Zdravilna učinkovina zdravila Memantine Mylan, memantin, je zdravilo za zdravljenje demence.
English: Why is Memantine Mylan approved?
Slovenian: Zakaj je bilo zdravilo Memantine Mylan odobreno?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine Mylan has been shown to have comparable quality and to be bioequivalent to Ebixa.
Slovenian: da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Memantine Mylan primerljivo raven kakovosti kot zdravilo Ebixa ter da mu je biološko enakovredno.
English: It is not intended to provide practical advice on how to use Memantine Mylan.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: How has Memantine Mylan been studied?
Slovenian: Kako je bilo zdravilo Memantine Mylan raziskano?
English: How is Memantine Mylan used?
Slovenian: Kako se zdravilo Memantine Mylan uporablja?
English: How does Memantine Mylan work?
Slovenian: Kako zdravilo Memantine Mylan deluje?
English: These measures help protect the environment.
Slovenian: Takšni ukrepi pomagajo varovati okolje.
English: It is very important that you read and understand the information about this serious reaction.
Slovenian: Zelo pomembno je, da preberete in razumete informacije o tej resni reakciji.
English: So it is very important to talk to your doctor about any changes in your health.
Slovenian: Zato je zelo pomembno, da se s svojim zdravnikom pogovorite o kakršnikoli spremembi vašega zdravstvenega stanja.
English: Date of latest renewal: 2 January 2011
Slovenian: Datum zadnjega podaljšanja: 2. januar 2011
English: You need to be aware of the extra risks:
Slovenian: Zavedati se morate dodatnih tveganj:
English: “Pull here” (with Alert card attached)
Slovenian: “Povlecite tukaj” (s pritrjeno opozorilno kartico)
English: ATC Code: J05AR04.
Slovenian: Oznaka ATC: J05AR04.
English: Your doctor will monitor the effectiveness of your treatment.
Slovenian: Zdravnik bo nadzoroval učinkovitost vašega zdravljenja.
English: Don't drive or operate machines unless you're feeling well.
Slovenian: Ne upravljajte vozil ali strojev, če se ne počutite dobro.
English: These adverse reactions have often been transitory.
Slovenian: Ti učinki so bili pogosto prehodni.
English: Risk Management Plan (RMP)
Slovenian: • Načrt za obvladanje tveganja (RMP)
English: 32 weeks 26 % 144 weeks
Slovenian: 32 tednov 144 tednov
English: See sections 4.4 and 4.8
Slovenian: Glejte poglavji 4.4 in 4.8.
English: ( see reverse of card)
Slovenian: (glej hrbtno stran kartice)
English: • deep, rapid, difficult breathing
Slovenian: • globoko, hitro, težko dihanje,